Netherlands Compounding Pharmacies Market
                     Netherlands Compounding Pharmacies Market - Size, Share, Outlook, and 
Opportunity Analysis, 2020- 2027
A pharmacy that is operated by a licensed pharmacist, licensed physician or a 
person under the guidance of a licensed pharmacist is called compounding 
pharmacy.The Netherlands compounding pharmacies market is estimated to 
account for US$ 520.5 Mn in terms of value by the end of 2027. Increasing 
prevalence of chronic diseases is expected to boost growth of the Netherlands 
compounding pharmacies market over the forecast period.
Request a sample copy of this report:- https://www.coherentmarketinsights.com/insight/request-
sample/3156 
Increasing prevalence of chronic diseases is expected to boost growth of 
the Netherlands compounding pharmacies market over the forecast period. For 
instance, according to Globocan 2018, 119,923 cases of cancer were registered 
in the Netherlands. Moreover, decreasing supply of essential drugs is also 
expected to propel growth of the market. For instance, according to Royal Dutch 
Society for the Promotion of Pharmacy (KNMP), 769 medicines were unavailable
at some stage during 2018, including 128 treatments that were taken out of 
circulation altogether.
Oral medication held dominant position in the Netherlands compounding 
pharmacies market in 2018, accounting for 62.9% share in terms of value, 
followed by topical medication.However, a major factor hindering growth of the 
Netherlands compounding pharmacies market is adoption of unsafe 
compounding practices such as compounding contamination and non-adherence
to GMP regulations.
Moreover, certain compounded drugs in the Netherlands have been associated 
with adverse drug reactions as they constitute drugs that are banned under 
pharmacovigilance measures. Adverse drug reactions prove detrimental to 
patient’s and related party’s confidence in compounded drugs. For instance, 
clioquinol—a drug used for controlling amoebiasis and infections with 
dientamoeba fragilis—is no longer registered through the Medicines Evaluation 
Board for systemic use in the Netherlands and is only available as a 
compounded drug. In 2015, according to Netherlands Pharmacovigilance Center,
use of clioquinol in compounded form led to 33 reports concerning adverse drug 
reactions.
Increasing GMP compliance is expected to offer lucrative growth opportunities for
players in the Netherlands compounding pharmacies market. Currently, 
inspection for adherence to GMP guidelines is only available for industrial 
manufacturing of drugs in the Netherlands. However, community compounding 
pharmacies need to adhere to best practice guidelines, as hospitals in the 
country are expected to outsource more drug compounding to the community 
compounding pharmacies.
Key players in the market can also focus on R&D of products related to geriatric 
and long-term care and innovative Hormone replacement therapy (HRT) 
applications to expand their product portfolio.Medication of adults segment in the 
Netherlands compounding pharmacies market was valued at US$ 136.6 Mn in 
2018 and is expected to reach US$ 287.8 Mn by 2027 at a CAGR of 8.6% during
the forecast period.
The market is witnessing increasing preference for HRT drugs for indications 
such as menopausal symptoms, men’s health (andropause), and weight loss. 
However, untested ingredients, possibility of microbiological contaminations, 
errors in defining dosages of hormones and declining reimbursements from 
government are some of the factors that may hamper demand for HRT drugs in 
the Netherlands.
In the Netherlands, products are primarily purchased from specialized 
compounding companies and products from major market players are in high 
demand compared to those of community compounding pharmacies. Moreover, a
majority of compounded drugs are outsourced to hospitals.Major players 
operating in the Netherlands compounding pharmacies market include, GMP 
Apotheek Mierlo Hout, Apotheek A15, Vemedia, and Fagron.
Key players in the market are focused on geographical expansion through M&A 
activities. For instance, in May 2019, Fagron entered into an agreement to 
acquire Central de Drogas, S.A. de C.V., a leading supplier of raw materials to 
compounding pharmacies and the pharmaceutical industry in Mexico.
Get the main link:-  https://www.coherentmarketinsights.com/market-insight/netherlands-
compounding-pharmacies-market-3156 
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: http://www.coherentchronicle.com/